



April 3, 2024

**BSE Limited**

Department of Corporate Services,  
P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
**MUMBAI - 400 001.**

**National Stock Exchange of India Limited**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**MUMBAI - 400 051.**

*Dear Sir/Madam,*

**Ref: Disclosures pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').**

**Sub: Change in Senior Management**

We are pleased to inform you about the appointment of Dr. Ranjana Pathak as Chief Quality Officer of the Company effective today, April 3, 2024. Dr. Pathak will oversee all aspects of quality and regulatory compliance for the Company's global operations.

We wish to inform you that Mr. Johnny Mikell, President - Global Head of Quality, will be retiring from the services of the Company effective June 30, 2024.

Disclosures in compliance with Regulation 30 read with Schedule III Part A Para A(7) of the Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, in respect of the above changes in the Senior Management are enclosed as **Annexure - 'A'**.

The above is for your information and dissemination.

Thanking you,

**For LUPIN LIMITED**

**R. V. SATAM**  
**COMPANY SECRETARY**  
**(ACS -11973)**

**Encl: - Annexure - 'A'**



**ANNEXURE - 'A'**

**Particulars as per Regulation 30 read with Schedule III Part A Para A(7) of the Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.**

<b>Sl. No.</b>	<b>Particulars</b>	<b>Description</b>
<b>1.</b>	reasons for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	<p><b>i.</b> Appointment of Dr. Ranjana Pathak as Chief Quality Officer of the Company.</p> <p><b>ii.</b> Retirement of Mr. Johnny Mikell, President - Global Head of Quality.</p>
<b>2.</b>	dates of appointment/re-appointment/ cessation & terms of appointment/ re-appointment;	<p><b>i.</b> The appointment of Dr. Pathak is effective April 3, 2024 and is not for a fixed term.</p> <p><b>ii.</b> The retirement of Mr. Mikell will be effective June 30, 2024.</p>
<b>3.</b>	brief profiles;	<p><b>i.</b> With over three decades of industry experience, Dr. Pathak has a wealth of knowledge and expertise. She will oversee all aspects of quality and regulatory compliance for the Company's global operations.</p> <p>Dr. Pathak's career includes serving as the Global Head for Quality and Pharmacovigilance at Dr. Reddy's. Prior to her tenure at Dr. Reddy's, Dr. Pathak served as the President &amp; Global Head of Quality, Medical Affairs and Pharmacovigilance at Cipla and has also held Global Quality and Compliance leadership positions at Watson/Actavis and Endo Pharmaceuticals in the U.S. Dr. Pathak has strong experience across generic and brand medicines across dosage platforms including injectables, inhalation products and biologics.</p> <p><b>ii.</b> Mr. Jonny Mikell headed the Company's Quality and regulatory Compliance function and related processes and practices.</p>
<b>4.</b>	disclosure of relationships between directors	<p><b>i.</b> Not applicable as Dr. Pathak is not a Board Member of the Company.</p> <p><b>ii.</b> Not applicable as Mr. Mikell was not a Board Member of the Company.</p>

**For LUPIN LIMITED**

**R. V. SATAM  
COMPANY SECRETARY  
(ACS -11973)**